Febuxostat and the Black Box Blues-Reference-Cited by-同舟云学术

Febuxostat and the Black Box Blues

Published:2019-07-11 Issue:6 Volume:1 Page:343-344
ISSN:2578-5745
Container-title:ACR Open Rheumatology
language:en
Short-container-title:ACR Open Rheuma

Author:

Abeles Aryeh M.¹^ORCID,Pillinger Michael H.¹

Affiliation:

1. School of Medicine New York University and New York University Langone Medical Center

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr2.11047

Reference9 articles.

1. US Food and Drug Administration.FDA adds boxed warning for increased risk of death with gout medicine Uloric (febuxostat).2019. URL:https://www.fda.gov/Drugs/DrugSafety/ucm631182.htm.

2. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout

3. Gout and cardiovascular disease: crystallized confusion

4. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update

5. Febuxostat and Cardiovascular Events: A Systematic Review and Meta-Analysis

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigating the Influence of Cosolvents on the Solubility of Febuxostat in Supercritical CO₂: Experimental Analysis and Artificial Intelligence Study;Journal of Chemical & Engineering Data;2024-07-01

2. Xanthine oxidase inhibitors treatment or discontinuation effects on mortality: evidence of xanthine oxidase inhibitors withdrawal syndrome;Frontiers in Pharmacology;2024-01-08

3. The landscape of pathophysiology guided therapeutic strategies for gout treatment;Expert Opinion on Pharmacotherapy;2023-12-05

4. Colchicine may be considered for the secondary prevention of cardiovascular disease;Drugs & Therapy Perspectives;2023-03-27

5. Review of Urate-Lowering Therapeutics: From the Past to the Future;Frontiers in Pharmacology;2022-08-23